NCT01947738View on ClinicalTrials.gov

Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)

PHASE1CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Healthy
Interventions
DRUG

VBY-891

Cathepsin S inhibitor

DRUG

Placebo

Trial Locations (1)

47710

Covance Evansville, Evansville

Sponsors

Collaborators (1)

LEO Pharma
All Listed Sponsors
collaborator

LEO Pharma

INDUSTRY

lead

Virobay Inc.

INDUSTRY

NCT01947738 - Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1) | Biotech Hunter | Biotech Hunter